Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Lucid Group Inc (LCID) vs Eli Lilly And Co (LLY) Price & Performance

Lucid Group IncTrade
Eli Lilly And CoTrade

Price performance (Past 24H)

Key statistics

Lucid Group Inc vs Eli Lilly And Co — how do they compare? Lucid Group Inc trades at $6.5 (market cap $2.64B), while Eli Lilly And Co trades at $1,223.26 (market cap $1.08T). The key difference: Eli Lilly And Co is far larger — about 409.1× Lucid Group Inc's market cap, and Eli Lilly And Co pays a 0.57% dividend while Lucid Group Inc pays none. Which is the better fit depends on your goals.

LCIDLLY
Market Cap
$2.64B$1.08T
Sector
Consumer CyclicalHealth
52-Week High
$24.77$1.24K
52-Week Low
$4.62$639.43
Enterprise Value
$5.54B$1.13T
Dividend Yield
0.57%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Lucid Group Inc

Lucid (LCID) trades at $6.495, down 1.74% on the day, amid a bearish technical signal and weak fundamentals. The company reported a Q2 2026 EPS miss of -$3.30 versus -$2.41 expected, with revenue growth overshadowed by negative gross and net income margins. Recent news highlights an operational reset targeting $1.4 billion in cash savings and a delayed EV launch, reflecting ongoing challenges in the competitive EV market.

The outlook remains high-risk due to persistent losses and cash burn, though analyst consensus suggests modest upside to a $10.50 price target. Investment opportunities hinge on successful cost-cutting and robotaxi initiatives, while risks include execution missteps and intense competition. With 66.7% of analysts rating Hold, cautious optimism is tempered by financial instability.

Eli Lilly And Co

Eli Lilly (LLY) trades at $1,231.58, up 3.87% in the past 24 hours, reflecting strong momentum near its 52-week high. The stock exhibits bullish technical signals with robust fundamentals, including 48% revenue growth in Q2 2026 and a net income margin of 33.53%. Recent news highlights legal actions against black-market drug sales and positive analyst sentiment following earnings beats.

Outlook remains positive with a consensus price target of $1,380, though high valuation ratios (P/E 40.79) and regulatory risks pose challenges. Earnings growth and pipeline advancements, like retatrutide, drive upside potential, but investors should monitor competitive pressures and execution risks.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Lucid Group Inc

Lucid Group Inc is a technology and automotive company. It develops the next generation of electric vehicle (EV) technologies. It is a vertically integrated company that designs, engineers, and builds electric vehicles, EV powertrains, and battery systems in-house using our own equipment and factory.

Read more on LCID

About Eli Lilly And Co

Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer

Read more on LLY